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Abstract
Bone sarcomas are tumours belonging to the family of mesenchymal tumours and constitute a highly heterogeneous tumour 
group. The three main bone sarcomas are osteosarcoma, Ewing sarcoma and chondrosarcoma each subdivided in diverse 
histological entities. They are clinically characterised by a relatively high morbidity and mortality, especially in children and 
adolescents. Although these tumours are histologically, molecularly and genetically heterogeneous, they share a common 
involvement of the local microenvironment in their pathogenesis. This review gives a brief overview of their specificities 
and summarises the main therapeutic advances in the field of bone sarcoma.
Keywords Osteosarcoma · Ewing sarcoma · Chondrosarcoma · Giant cell tumour of bone · Tumour microenvironment · 
Immunotherapy · Clinical trials
Introduction
Bone sarcomas belong to a mesenchymal tumour family 
originating from bone and composed by highly heterogene‑
ous subtypes. These tumours represent < 0.2% of malignant 
tumours registered in the EUROCARE database, and are 
considered as rare cancers and orphan tumours [1]. The three 
main entities are osteosarcoma, Ewing sarcoma and chon‑
drosarcoma [2–4]. Mesenchymal stem cells (MSCs) located 
in most of the tissues have the ability to differentiate into 
various mesenchymal tissues including bone and cartilage 
[5]. Bone marrow and the bone environment are particularly 
rich in MSCs, which generate stromal cells thus supporting 
the haematopoiesis in addition to the bone maintenance [6, 
7]. This process is in fact controlled by specific transcription 
factors expressed during the differentiation programme of 
MSCs, which orientate their differentiation towards deter‑
mined cell lineages. Thus, the runx2 and sox9 master genes 
induce a hierarchical regulation of downstream genes modu‑
lated by MSCs and drive the differentiation of MSCs into an 
osteoblastic and chondroblastic lineage, respectively [4, 5]. 
The present review aims to give an overview on the main 
characteristics of bone sarcomas with a specific focus on the 
most recent clinical developments.
Main Biological Characteristics of Bone 
Sarcomas
Bone sarcoma genesis can be explained by a conjunction 
between a minimum of one oncogenic event and an ade‑
quate microenvironment leading to the emergence of cancer, 
followed by its growth and potential migration to distant 
organs. Oncogenic events at the gene expression level (e.g. 
mutation, duplication, translocation) occurring during MSC 
differentiation increase the risk of their transformation to 
cancerous cells and result in the emergence of malignant 
osteoblastic or chondroblastic malignant cells. Indeed, 
osteosarcoma and chondrosarcoma cells express runx2 and 
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sox9 in a similar manner than their non‑malignant homo‑
logues [8–11]. This expression of master genes in addition 
to their embryologic origin and their morphology strongly 
establish their close relationship with MSCs (Fig. 1). In this 
context, osteosarcoma cells originate from MSCs that are 
more or less committed to the osteoblast differentiation pro‑
gramme in which the oncogenic events occur. Consequently, 
osteosarcoma cells can express osteoblastic markers such as 
alkaline phosphatase, osteocalcin or bone sialoprotein and 
show a strong capacity to form osteoid tissue and induce 
the mineralisation of extracellular matrix. Chondrosarcoma 
cells share common features with chondrocytes and express 
chondrocyte markers such as type II collagen or aggre‑
can (Fig. 1). Because chondrosarcoma cells are cytologi‑
cally and phenotypically related to chondrocytes, they are 
able to produce cartilaginous matrix into which malignant 
chondrocytes become encased. Chondrosarcoma can form 
benign lesions in which the Hedgehog signalling pathway 
(such as EXT1 and EXT2 involved in the endochondral ossi‑
fication) is dysregulated and evolve into malignant entities 
[12–14]. While osteosarcoma and chondrosarcoma can be 
considered as the result of a disturbed differentiation pro‑
gramme of MSCs, the origin of Ewing sarcoma is more 
controverted. Indeed, Ewing sarcoma cells are character‑
ised by the expression of a fusion protein resulting from a 
chromosomal translocation between the EWS gene on chro‑
mosome 2 and a gene of the ETS family and consequently 
have been initially associated with the primitive neuroecto‑
dermal family of tumours [15]. However, the main frequent 
location of Ewing sarcoma in bone and the functional con‑
sequence of EWS–FLi1 silencing in Ewing sarcoma cells fed 
the controversy and put a label of mesenchymal origin on 
Ewing sarcoma [15]. Indeed, Tirode et al. showed that the 
EWS–FLI1 silencing in different Ewing cell lines resulted in 
the differentiation of sarcoma cells into mesenchymal line‑
ages and more particularly into adipogenic and osteogenic 
lineages [16]. To date, its origin remains elusive with three 
potential hypotheses: neural crest stem cells [17], embryonic 
osteochondrogenic progenitor cells [18] or MSCs [16, 19]. 
Numerous pre‑clinical models based on in vitro approaches 
and in vivo investigations (e.g. rat, mouse, zebrafish) mim‑
icking the human disease have been proposed and are cur‑
rently used to study the pathogenesis of bone sarcomas and/
or for screening new drugs [20–28].
Main Clinical Characteristics of Bone 
Sarcomas
Osteosarcoma, Ewing sarcoma and chondrosarcoma are 
separated into three different clinical entities identifiable 
by the patient populations affected, their localisation and 
their biological characteristics (Table 1). Osteosarcoma 
is the most frequent malignant primary bone tumour with 
a higher incidence in adolescent and young adults. Two 
peaks of incidence are conventionally described: (i) a 
main peak at 18 years and (ii) a second peak at 60 years 
with poor prognosis corresponding frequently to second‑
ary osteosarcoma developed after radiotherapy or after 
Paget disease of bone [2, 3]. All osteosarcomas are char‑
acterised by the presence of a mineralised osteoid matrix 
produced by cancer cells and which results in the typical 
radiographic appearances called “sunburst” pattern [4, 29]. 
Osteosarcoma are very heterogeneous tumours (intra‑ and 
inter‑tumoural heterogeneity) as revealed by the multiple 
histological subtypes according to the degree of cancer 
cell differentiation and consequently the quality of the 
extracellular matrix secreted (e.g. osteoblastic, chond‑
roblastic, fibroblastic, telangiectatic osteosarcoma). The 
main affected areas of osteosarcoma are the metaphysis 
of the long bones with a preference to the proximal end of 
the tibia/fibula corresponding to the location of the growth 
plate. Genetic analyses confirmed the high heterogeneity 
of osteosarcoma [30–32]. Bousquet et al. identified for 
instance more than 80 point mutations and some deletions 
related to more than 80 genes [30]. Kovac et al. interest‑
ingly identified a BRCAness signature in osteosarcoma 
which could be exploited as a new therapeutic targeting 
[31]. The overall survival of osteosarcoma patients is 
very dependent on their metastatic status at the time of 
diagnosis with a survival rate for patients with localised 
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Fig. 1  Origin of bone sarcomas. Based on the current knowledge, 
osteosarcoma, Ewing sarcoma and chondrosarcoma share a common 
mesenchymal origin. According to their differentiation level and in 
association with oncogenic events and an adapted microenvironment 
their common precursor, a “mesenchymal stem cell” could be trans‑
formed into an osteosarcoma, chondrosarcoma or an Ewing sarcoma. 
Sox9 Sry‑related high‑mobility group box (Sox) transcription factor 9 
related to chondrogenic differentiation, Runx2 runt‑related transcrip‑
tion factor 2 related to osteoblastogenesis, ALP alkaline phosphatase, 
OC osteocalcin, BSP bone sialoprotein
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metastases are detected, survival drops to 30% (Table 1). 
Around 10–20% of patients show clinically detectable 
metastases at time of diagnosis and 85–90% are located 
in the lungs.
Ewing sarcoma is the second main represented bone 
sarcoma with 0.3/100,000/year. This bone sarcoma sub‑
type accounts for 2% of childhood cancers, is more pre‑
dominant in male than female with a sex male/female ratio 
around 1.5 and has a peak of incidence at 15 years. Sixty 
percent of Ewing sarcomas develop in flat bones and 40% 
affect the metaphysis of long bones (Table 1). Similar to 
osteosarcoma, the overall survival is also associated with 
the metastatic status of patients. For localised tumours, the 
overall survival is 50–60% at 5 years, which drops to only 
around 20% for metastatic sarcoma. At time of diagnosis, 
20–25% of patients show clinically detectable metastases 
[33–35]. Although Ewing sarcoma is the most homogene‑
ous entity among bone sarcomas, composed of undifferen‑
tiated round cancer cells characterised by CD99‑, FLI1‑, 
HNK1‑ and CAV1‑positive immunostaining associated 
with limited stromal components [36], recent work dem‑
onstrated in contrast their heterogeneity [37–40]. Previous 
studies highlighted only a few recurrent somatic mutations 
in Ewing sarcomas (TP53, STAG2, CDKN2) [38, 41, 42]. 
However, more recent studies by Zhang et al. used next‑
generation sequencing (Ion AmpliSeq™ Cancer Hotspot 
Panel v2) to identify a series of five new mutations (KDR, 
STK11, MLH1, KRAS and PTPN11) related to a higher 
proliferation index and revealing a higher tumour hetero‑
geneity than initially suspected [37]. This heterogeneity is 
not restricted to the genetic patterns but can be extended 
to epigenetic profiles [39]. Indeed, Sheffield et al. showed 
heterogeneous DNA methylation profiles between differ‑
ent tumours, which could reflect a continuum between 
mesenchymal and stem cell signatures in link with the 
EWS–FLI1 signature [39]. In addition, the expression 
levels of EWS–FLi1, which are variable in a tumour tissue, 
have a functional impact on cell migration. EWSR1–FLi‑
1high cells are characterised by high proliferation activ‑
ity, while EWSR1–FLi1low have a marked propensity to 
migrate, invade and metastasise [40].
Chondrosarcoma is the third entity of bone sarcoma in 
term of incidence with around 0.2 new cases per 100,000 
each year and similar incidence between male and female 
(Table 1). Similar to all bone sarcomas, several subtypes 
can be identified according to their histological character‑
istics [43–46] and are classified as low, intermediate or 
high grade on the basis of histopathological features [47]. 
Chondrosarcomas are characterised by a tumour chon‑
drocyte‑derived hyaline‑like extracellular matrix, which 
eventually encases the cancer cells. The tumour tissue is 
organised in a mosaic of lobules separated by fibrous tis‑
sue. In addition, chondrosarcomas exhibit low vascularisa‑
tion in contrast to osteosarcoma and Ewing sarcomas. Het‑
erogeneity is also a hallmark of chondrosarcomas, which 
are associated with a complex cytogenetic signature [48, 
49]. Thus, somatic mutations in isocitrate dehydrogenase 
(IDH)‑1 or ‑2 are frequent (around 56%) in central and 
periosteal cartilaginous tumours and absent in endochon‑
droma [50]. In addition to mutations in IDH1, IDH2, EXT 
(exostosin) and more conventional genes associated with 
cancer progression such as TP53 or Rb1, Tarpey et al. 
identified COL2A1 mutations (insertions, deletions and 
rearrangements) in the third cases [51]. The principal 
localisations of chondrosarcomas are pelvic bone, scapula 
and long bones (Table 1). While high‑grade chondrosar‑
comas can be associated with metastases, these tumours 
are characterised by a high rate of local recurrence and 
consequently by a high morbidity [52, 53]. Osteosarcoma, 
Ewing sarcoma and chondrosarcoma are then character‑
ised by a marked heterogeneity at the histological, genetic 
and epigenetic levels.
Table 1  Characteristics of the three main bone sarcomas
a Source: ref [2]
Tumour type Ratio 
male/
female
Frequencya Peak of incidence (years) Principal localisations Survival rate







Metaphysis of long bones
Distal end of femur + proximal 
end tibia/fibula (60%)
60–70% after 5 years
30% after 5 years (with lung 
metastases)
Ewing sarcoma 1.5 0.3/100,000/year 15 Flat bones (60%)
Metaphysis of long bones 
(40%) and soft tissues
66% at 5 years and 20% at 
5 years for poor responders
Chondrosarcoma 1 0.2/100,000/year 45 Pelvic bone, femur, proximal 
humerus, scapula
50–60% at 10 years according 
the histological grade
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Etiology of Bone Sarcomas: The 
Microenvironment as the Driver of Cancer 
Progression
In addition to c‑fos which has been associated with osteo‑
sarcoma formation due to its contribution in osteoblast 
differentiation [54, 55], some genetic predispositions have 
been linked with osteosarcoma development in hereditary 
syndromes such as Li‑Fraumeni (p53 mutation) [56], Roth‑
mund‑Thompson [57], Werner [58] or Bloom syndromes 
(mutations of helicase genes) [59, 60], or retinoblastoma 
familial cancers [61]. Hereditary multiple exostoses 
(familial osteochondromatosis or diaphyseal aclasis) is an 
inherited genetic disease associated with osteochondromas 
and with EXT1 and EXT2 mutations [14, 62]. Even if sev‑
eral studies evaluated the risk of malignant transformation 
of multiple exostoses, the most recent study identified this 
risk at relatively low level (2.7%) with the development 
of low‑grade chondrosarcomas [63]. However in most of 
the cases, patients do not show any predisposition genes 
and bone sarcomas are sporadic cases which could be 
explained by a close relationship with their local micro‑
environment altered during the malignant transformation 
process [64–68]. The “seed and soil” theory proposed by 
Stephen Paget at the end of the nineteenth century gives a 
partial explanation of bone sarcoma formation [69]. At the 
early stage of the disease, proliferation of bone sarcoma 
cells in the bone environment leads to the dysregulation of 
the balance between osteoblasts and osteoclasts, in favour 
of an exacerbated osteoclast differentiation and local 
bone resorption. In turn, resorptive osteoclasts release 
pro‑tumoral factors (e.g. cytokines, extracellular matrix 
components) initially trapped into the organic matrix of 
bone tissue [70]. The demonstration of this vicious cycle 
between osteoclasts and bone sarcoma cells has stimu‑
lated numerous pre‑clinical and clinical investigations that 
revealed the decrease of tumour bone sarcomas after tar‑
geting of osteoclasts using anti‑resorptive agents [71–75]. 
In addition to their anti‑resorptive activities, nitrogen‑con‑
taining bisphosphonates could have a direct anti‑prolif‑
erative activity on cancer cells [76, 77]. On the contrary, 
Endo‑Munoz et al. showed the deleterious effect of osteo‑
clastogenesis inhibition after zoledronic acid treatment 
which was associated with an increase of lung metastases 
in an osteosarcoma model [78]. The role of osteoclasts in 
bone sarcoma development is still unclear and osteoclasts 
could act as a pro‑tumoral factor in the early stage of the 
disease due to their pro‑angiogenic activity [79] and could 
exert the opposite role at a later stage of the disease [80].
Bone sarcoma development could be explained by the 
conjunction of multiple factors: (i) one or more onco‑
genic events from which the malignant transformation 
is initiated. The risks of genetic aberrations at the gene 
expression level (e.g. mutation, deletion, amplification) 
could increase with the proliferation rate of the cells of 
interest such as MSCs/osteoblasts during bone growth. A 
first mutation could lead to a chromosomal instability and 
consequently to the appearance of new oncogenic events 
[31]. (ii) A favourable microenvironment is a prerequisite 
for the growth of cancer cells. The differential repartition 
of bone sarcomas according to their subtypes are in favour 
of this theory. Furthermore, numerous studies demon‑
strated that MSCs induce pro‑proliferative effects on bone 
sarcoma and promote osteosarcoma stemness strengthen‑
ing the “seed and soil” theory [81, 82]. Local acidosis 
derived from the tumour growth and tumour‑associated 
osteolysis has in return a strong impact on the stemness of 
MSCs [83, 84]. The bilateral dialogue established between 
cancer cells and their neighbours is a central aspect of 
bone sarcoma development. The diverse modes of com‑
munication include soluble factors (e.g. chemokines, 
cytokines), direct cell interactions and extracellular vesi‑
cles [64–66]. Gap junctions are intercellular channels 
composed of transmembrane proteins named connexons 
that allow direct intercellular communication between 
two adjacent cells. Recent data investigated at the single‑
cell level showed intercellular communications through 
gap junctions between osteosarcoma cells and various 
other cell types [85]. Functional gap junctions have been 
observed between osteosarcoma cells and MSCs depend‑
ing on their differentiation levels, and between cancer 
cells and endothelial cells. In contrast, while all bone cells 
express gap junctions, no gap junction‑dependent commu‑
nication has been demonstrated with macrophages, oste‑
oclasts or osteocytes [86–88]. Gap junctions are clearly 
involved in the tumour development and the loss of con‑
nexin43 expression in Ewing sarcoma cells favours the 
development of the primary tumour growth [89]. Another 
way of cell communication is transfer of extracellular 
vesicles loaded with proteins, mRNA and microRNA. 
Thus, it has been suggested that osteosarcoma cells are 
able to resist the effects of chemotherapeutic treatment 
such as doxorubicin by transferring exosomes carrying 
specific multidrug resistance factors (e.g. MDR‑1, Pgp) 
from resistant to non‑resistant cancer cells [90]. Recently, 
Baglio et al. described the education of MSCs by tumour‑
secreted extracellular vesicles [91]. These authors dem‑
onstrated the ability of osteosarcoma cells to incorporate 
TGF‑β into extracellular vesicles which induced produc‑
tion of IL‑6 in MSCs. IL‑6 is in turn associated with an 
increase of tumour growth [92]. A vicious cycle is then 
established between MSCs and sarcoma cells through the 
release of extracellular vesicles.
The bone sarcoma microenvironment is not restricted 
to MSCs but is a very complex and dynamic environment 
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(Fig. 2). This environment can be described as “niches” 
including bone, vascular and immune niches and more 
specific niches such as muscles and lung parenchyma for 
invading and metastatic cells. Even though there is no evi‑
dence of the correlation between the vessel density and the 
metastatic process in bone sarcomas, endothelial cells are 
strongly involved in the intra/extravasation of cancer cells. 
Recently, new regulators including brain, neuronal network 
and neurotrophic factors should be added to the list. It is now 
well recognised that the brain can act as a master regulator of 
bone mass [93, 94]. Bone remodelling is indeed regulated by 
a rich innervation, which is the source of neurotrophic fac‑
tors, hormones and neurotransmitters [95]. Released locally 
or into the blood stream, these soluble factors could target 
bone sarcoma cells [96, 97]. The most recent evidence has 
been given by Punzo et al. who showed the anti‑prolifer‑
ative, pro‑apoptotic and anti‑invasive effects of endocan‑
nabinoid and endovanilloid systems in osteosarcoma [98] 
(Fig. 2). The bone environment is relatively specific to bone 
sarcomas and bone cells have been suspected to contrib‑
ute to their development. Indeed, as described above, the 
blockade of bone resorption by bisphosphonates inhibits the 
tumour growth in pre‑clinical models of osteosarcoma [92] 
and Ewing sarcoma [71] and slows down recurrent tumour 
progression after intralesional curettage in chondrosarcoma 
[76, 99]. Unfortunately, the results of a phase III clinical 
trial associating conventional chemotherapy and bisphos‑
phonate (zoledronate) do not recommend this therapeutic 
strategy in osteosarcoma [100]. The lack of significant effi‑
cacy can be explained by the disparity of bisphosphonate 
or RANKL‑blocking antibody efficacy observed using the 
parameters of bone remodelling in different mouse strains 
[101]. Alternatively, bisphosphonates could modulate 
macrophage differentiation through complex mechanisms. 
Tumour‑associated macrophages (TAMs) can be subdivided 
in two types of populations, M1‑polarised macrophages 
considered as antitumour effectors and M2‑polarised mac‑
rophages, which are defined as pro‑tumour modulators due 
to their positive impact on the neoangiogenic process [102]. 
In breast cancer models, it has been shown that cancer cells 
secrete soluble factors modulating macrophages towards the 
M2 state. Zoledronate counteracts this differentiation and 
- Endothelial cells 
- Perivascular cells 
- Lymphocytes 
- Macrophages 





- Neurotrophic factors and central 
regulation of bone remodelling 
- Fibroblasts and 
 extracellular matrix 
- Soluble factors and 
 extracellular vesicles 
- Rhabdomyocytes 
 and leiomyocytes 
- Pneumocytes 
Fig. 2  The tumour microenvironment contributes to the control of 
bone sarcoma formation, their recurrence and associated metastatic 
process. The bone sarcoma microenvironment is composed of highly 
diversified cell populations forming specific local niches: vascular 
niche, immune niche, bone niche, muscular and pulmonary niches 
(e.g. metastatic niches), neuronal control and activity of neurotrophic 
factors. These various cell types establish a mutual dialogue with sar‑
coma cells through physical contact, the release of soluble factors or 
the formation of extracellular vesicles. All these communications will 
lead to strong alterations of the microenvironment (e.g. qualitative 
modifications of the extracellular matrix) and the behaviour of can‑
cer cells, which increase their proliferation, and/or invasion/migration 
properties
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favours a cytotoxic immune response linked with the differ‑
entiation of TAMs towards the M1 subtype [103]. In meso‑
thelioma, zoledronate impairs the polarisation of TAMs to 
the M2 phenotype but leads to the accumulation of immature 
myeloid cells, which could reduce its effects [104]. In bone 
sarcoma, TAMs also appeared as key effectors of the patho‑
genesis [105–107]. Indeed, the macrophage infiltration in 
osteosarcoma is correlated with metastatic suppression [105] 
and osteosarcoma cells dysregulate the balance of M1/M2 
macrophages [106]. An abundant M2 macrophage infiltrate 
is consequently in favour of a metastatic profile [106]. In 
Ewing sarcoma, the targeting of TAMs by liposome‑encap‑
sulated clodronate that inhibits simultaneously M1 and M2 
macrophages leads to a decrease of tumour growth [107]. 
Overall, these results demonstrate the key role of mac‑
rophages which regulate the development of bone sarcoma 
according to their number and M1/M2 phenotype. The role 
of the immune niche in bone sarcoma development is not 
restricted to TAMs and is also controlled by dendritic cells, 
tumour infiltrating lymphocytes or mast cells [108–110].
Recent Therapeutic Developments
Although current conventional treatments are relatively 
similar for osteosarcoma and Ewing sarcoma combining 
chemotherapy and surgery, the mainstay of local tumour 
control in chondrosarcoma is surgery with adequate mar‑
gins (margins of normal tissue). Indeed, chemotherapy and 
radiotherapy are ineffective in the treatment of local and 
advanced chondrosarcoma patients. Consequently, both ther‑
apeutic approaches have limited impact in the management 
of these patients [111]. Unfortunately, adequate margins can 
only be achieved in 45–75% of patients. Inadequate margins 
are related to a high risk of local recurrence. Recent work 
validated the cryosurgery after intralesional curettage for 
low‑grade chondrosarcoma. The technique appears safe and 
effective in selected patients [111]. Chemotherapy is rec‑
ommended for high‑risk chondrosarcoma and dedifferenti‑
ated chondrosarcoma but there is no recognised consensus 
defining the protocol and time schedule. The conventional 
therapeutic approach to osteosarcoma and Ewing sarcoma 
combines surgery (preoperative or neoadjuvant) and after 
chemotherapy (postoperative or adjuvant) and long‑term 
(6–12 months) polychemotherapy [112–115]. The con‑
ventional cocktail used in osteosarcoma is composed by 
a minimum of three drugs (reference combination: doxo‑
rubicin, cisplatin, methotrexate). Ifosfamide is the fourth 
drug used in osteosarcoma. Radiotherapy can be used when 
adequate surgery is impossible and for high‑risk locations 
(e.g. spine); however, osteosarcomas are usually consid‑
ered as radioresistant. In Ewing sarcoma, chemotherapy 
includes vincristine, ifosfamide, doxorubicin and etoposide. 
In addition, patients will receive radiotherapy since Ewing 
sarcoma responds relatively well to irradiation [116]. Several 
on‑going clinical trials are studying new regimens of high 
doses of chemotherapy in combination with radiotherapy 
(Table 2). However, most conventional chemotherapy com‑
monly results in relatively poor therapeutic responses, which 
has led to the development of new compounds with new 
therapeutic targets (Tables 2, 3; Fig. 3).
Novelties in Osteosarcoma and Ewing Sarcoma
New therapeutic approaches have been proposed and are 
currently on‑going to improve the survival rate of osteosar‑
coma patients [109, 112]. Similar strategies are now pro‑
posed for Ewing sarcoma patients.
New Formulation of Chemotherapeutic Agents
In order to reduce its cardiotoxicity, liposomal doxorubicin 
formulations have been designed and show similar efficacy 
than conventional doxorubicin [117]. Liposomal doxoru‑
bicin is currently tested in phase I in refractory paediatric 
solid tumours (Table 2). Liposomal formulation can also be 
used for the modulation of drug pharmacology profiles such 
as irinotecan for which its pharmacology has likely limited 
its clinical activity. Positive benefit of irinotecan sucrosofate 
liposomes was demonstrated in a xenograft model of Ewing 
sarcoma and is assessed in a Phase trial (NCT02013336) 
[118].
Tyrosine Kinase Inhibitors as Multiple Target Drugs
It is recognised that cytotoxic cancer agents can kill prolif‑
erating cells by damaging DNA or microtubules. Although 
numerous cancer cells are sensitive to chemotherapy despite 
their low proliferation, called «the proliferating rate para‑
dox» by Mitchison TJ, quiescent cells are usually insensi‑
tive to cytotoxic agents [119] and can be reactivated in an 
adequate microenvironment [29, 84, 91]. In this context, the 
disruption of the dialogue between cancer cells and their 
microenvironment is a promising therapeutic approach in 
bone sarcomas. Migration, survival and proliferation are 
controlled by a complex internal cell machinery but also by 
several external factors such as cytokines or growth‑activat‑
ing tyrosine kinase receptors [120]. Several clinical trials 
are in progress to assess tyrosine kinase inhibitors which 
are considered as multi‑target drugs (Tables 2, 3; Fig. 3). 
Regorafenib an oral multikinase inhibitor targeting angio‑
genic factors (VEGFR1‑3, TIE2), oncogenic kinases (KIT, 
RET, RAF) and pazopanib inhibiting VEGFR, PDGFR 
and cKIT are going to be assessed in osteosarcoma (Fig. 3) 
[120, 121]. First therapeutic response has been described 
in three metastatic osteosarcoma [122] and Ewing sarcoma 
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[123] patients treated with pazopanib. Similarly, regorafenib 
showed its antitumour activity in osteosarcoma in a phase I 
clinical trial [124], a phase II is in progress and will include 
126 patients treated daily with oral 160 mg regorafenib. 
Erlotinib targeting the EGFR, cabozantinib blocking cMET 
and entrectinib, a selective inhibitor of TrkA, B and C, C‑ros 
oncogene 1 and ALK are also in phase II in rare tumours 
including Ewing sarcoma (Table 2).
Bone Targeting
Ewing sarcoma cells activate osteoclastogenesis followed by 
increased bone resorption and in this context the blockade 
of osteoclast activation by a bisphosphonate showed thera‑
peutic benefit in a pre‑clinical model of Ewing sarcoma [71]. 
A phase III clinical trial including more than 1150 patients 
treated with zoledronate is currently on‑going with primary 
completion by March 2019. Radium‑223 (223Ra) is an alpha‑
emitting radiopharmaceutical compound which showed cal‑
cimimetic properties and consequently has intrinsic calcified 
tissue‑targeting properties. Based on these specificities, the 
bone matrix is the preferential site of biodistribution. The 
first clinical evidence of response to radium‑223 in osteo‑
sarcoma has been published by Subbiah et al. who described 
a reduction of bone pain and bone‑remodelling parameters 
after treatment [125]. A phase I/II clinical trial is on‑going 
(NCT01833520, «Phase I Dose Escalation of Monthly Intra‑
venous Ra‑223 Dichloride in Osteosarcoma») to determine 
the maximum tolerated dose of radium‑223 dichloride for 
treating osteosarcoma patients. Fifteen patients have been 
enrolled and were treated with a starting dose of radium‑223 
dichloride (50 kBq/kg i.v. over several minutes on day 1 of 
each 4‑week cycle). The final completion will be at the end 
of 2018 [112].
DNA Repair Targeting
Poly(ADP‑ribose) polymerase 1 (PARP1) is a key pro‑
tein involved in DNA repair especially in DNA repair of 
single‑strand breaks. In 2012, Garnett et al. have reported 
a high sensitivity of Ewing sarcoma cells to PARP inhibi‑
tors [126]. Based on this interesting observation, a first 
phase II trial was set up in Ewing sarcoma. Unfortunately, 
the results revealed the absence of efficacy of olaparib as 
a single agent [127]. However, pre‑clinical studies demon‑
strated promising benefit when combining PARP inhibitors 
with other targeting pathways (e.g. IGF1 inhibition, Tra‑
bectedin, temozolomide) and justified several phase I clini‑
cal trials (NCT01858168, NCT02044120) [128]. In 2015, 
Kovac et al. studied 31 osteosarcoma samples by exosome 
sequencing and showed for the first time recurrent mutation 
signatures of BRCA deficiency [31]. This observation could 
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of PARP inhibitors in osteosarcoma and clinical trials are 
in discussion.
Immunotherapies
The immune system plays a key role in cancer and immune 
cells recruited by cancer cells (e.g. lymphocytes, dendritic 
cells, macrophages) are responsible for a local immune tol‑
erance and T lymphocytes infiltrating osteosarcoma tissues 
[110]. Programmed cell death ligand 1 (PDL‑1) is a cell‑
surface protein that represses the cytotoxic  CD8+ T‑cell‑
mediated immune response. PDL‑1 is frequently highly 
expressed by cancer cells and has become a strategic target 
in oncology [109, 129, 130]. PD‑1 and PDL‑1 have also 
been reported to be expressed by some osteosarcoma, Ewing 
sarcoma and giant cell tumours of bone as well as in soft‑
tissue sarcoma [131]. Shen et al. analysed the expression of 
PDL‑1 in osteosarcoma samples and revealed its expression 
in a subset of osteosarcoma as well as a correlation between 
PDL‑1 expression and T lymphocyte infiltration [132]. More 
recently, Sandara et al. demonstrated an increased PDL‑1 
expression and T‑cell infiltration in metastatic high‑grade 
osteosarcoma strengthening the clinical interest of PDL‑1/
PD‑1 inhibition in osteosarcoma [133]. Paoluzzi et al. ret‑
rospectively analysed a cohort of 28 patients with relapsed 
metastatic/unresectable soft‑tissue and bone sarcomas, who 
were treated with i.v. nivolumab (anti‑PD1) 3 mg/kg every 
2 weeks with or without pazopanib at 400–800 mg daily 
[134]. They observed three partial responses, nine stable 
disease and twelve patients had progression of disease. The 
authors concluded that a clinical benefit was observed in 
50% of the evaluable patients. Based on these observations, 
the assessment of two anti‑PD1 antibodies, pembrolizumab 
(NCT02301039) and nivolumab (NCT02304458) are in pro‑
gress in osteosarcoma (Fig. 3). PD‑1 inhibitor (nivolumab) 
is currently assessed in Ewing sarcoma in combination with 
an anti CTLA‑4 antibody (Ipilimumab) (Table 2).
Preparation of immune cells such as dendritic cells, 
loaded T lymphocytes and NK (natural killer) cells are 
also in evaluation in phase I/II clinical trials in osteosar‑
coma (Fig. 3) and Ewing sarcoma (Table 2). The main goal 
of these studies is to lift the local immune tolerance and 
to reactivate the immune response against cancer cells. 
Thus, a pilot study (NCT02409576) in which activated 
haploidentical NK cells will be administered in 20 sar‑
coma patients is currently being carried out. The primary 
outcome will be clinical response (estimated primary com‑
pletion date: end 2018).
Macrophage infiltration contributes to the control of 
osteosarcoma growth [105–107]. From this observation, 
several therapeutic strategies have been developed. One of 
the more “polemical” agents is Mifamurtide (L‑MTP‑PE), 
a synthetic analogue of a bacterial wall component able to 
activate macrophages resulting in improvement of overall 
survival by around 10% in combination with chemotherapy 
[113]. However, due to some controversy on the design of 
the study, its use is not universally admitted and a phase 
II/III clinical trial is on‑going (NCT01459484). This trial 
will enrol more than 200 patients. Mifamurtide [2 mg/m2 
twice a week for the first 3 months, then weekly for the 
next 6 months (total length of treatment 44 weeks)] will be 
added as post‑surgery regimen in association with chemo‑
therapy. Patients will be identified as good or bad respond‑
ers according to the expression levels of P‑glycoprotein. 
The estimated primary completion date is beginning of 
2020.
Fig. 3  Recent on‑going clinical 
trials in osteosarcoma. Numer‑
ous therapeutic approaches are 
in clinical development and are 
based on specific and direct tar‑
geting of cancer cells (e.g. DNA 
repair, cell cycle or glycoprotein 
targeting), or indirect targeting 
of cancer cells by modulation 
of their microenvironment (e.g. 
immunotherapies). After inte‑
gration in extracellular tumour 
bone matrix, alpha radiothera‑
peutic agents can indirectly kill 
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Fusion Protein Targeting
Ewing sarcoma are characterised by a t(11; 22) (q24; q12) 
translocation resulting in the EWS/FLi1 fusion gene con‑
sidered as a driver gene for the disease. New therapeutic 
approaches targeting EWS/FLi1 gene or the corresponding 
protein have been set up (Table 2).
Based on the pre‑clinical data on EWS–Fli1 silencing 
[13, 14], a phase I clinical trial has been designed for the 
treatment of Ewing sarcoma patients by a shRNA EWS/Fli1 
type lipoplex (NCT02736565, Table 2). A dose escalation 
study of intravenous shRNA EWS/Fli1 type lipoplex (up 
to 0.156 mg/kg of DNA/single dose) will be carried out. 
The drug will be administered twice a week for 4 weeks 
for a total of eight infusions per cycle followed by 2 weeks 
of rest. Adverse effect and the therapeutic response will be 
assessed (estimated study completion date: end 2019). Simi‑
larly, TK216 is a chemical compound developed to inhibit 
downstream effects of the EWS–FLi1 transcription factor 
(NCT02657005, Table 2). The maximum tolerated dose will 
be determined in a phase I clinical trial.
Cyclin‑Dependent Kinase Inhibitors
CDK4 and CDK6 are kinases involved in the control of 
the cell cycle and act in G1 phase. In order to block cell 
proliferation, cyclin‑dependent kinase inhibitors have been 
designed. Among them, Abemaciclib inhibits CD4 and 
CDK6 and induces a cell cycle arrest in G1 phase by acting 
on Rb phosphorylation. Fifty patients including osteosar‑
coma and Ewing sarcoma patients will be enrolled in a phase 
I clinical trial (NCT02644460) to determine the maximum 
tolerated dose (estimated study completion date: 2020).
Disialoganglioside (GD2) Targeting and Drug 
Resistance (gpNMB)
A recent study revealed that most osteosarcoma and Ewing 
sarcoma expressed GD2, which is suspected to enhance 
tumour aggressiveness [135]. A phase II clinical study is in 
progress [NCT02502786, «Humanized monoclonal antibody 
3F8 (Hu3F8) with Granulocyte‑Macrophage Colony‑Stimu‑
lating Factor (GM‑CSF) in the treatment of recurrent osteo‑
sarcoma»]. Patients are treated with three doses of hu3F8 
(2.4 mg/kg/dose for 3 days) and 10 days of GM‑CSF (five 
cycles maximum). The primary outcome is the event‑free 
survival. Glycoprotein non‑metastatic melanoma protein 
B (gpNMB) is highly expressed in solid tumours and pro‑
motes metastatic progression by modulation of invasion and 
migration. A phase II clinical trial (NCT01353625) is evalu‑
ating the therapeutic benefit of Glembatumumab vedotin, 
an antibody‑drug conjugate targeting gpNMB, in osteosar‑
coma patients. Patients with recurrent disease or refractory 
to conventional therapy have been included. The primary 
outcome is the dose‑limiting toxicity and non‑tolerated dose 
(estimated primary completion date: end 2018).
Novelties in Chondrosarcoma
Chondrosarcoma comprises chemo‑ and radioresistant 
tumours with high risk of recurrence and surgery remains 
the treatment of choice. Due to their common origin, numer‑
ous new clinical approaches are similar to those proposed for 
osteosarcoma and Ewing sarcoma (Table 3). Because chon‑
drosarcoma cells are sensitive to soluble factors produced by 
their microenvironment and activate various tyrosine kinase 
receptors, several tyrosine kinase inhibitors are clinically 
assessed alone or in combination: regorafenib, pazopanib, 
dasatinib (Bcr‑Abl and Src family tyrosine kinase inhibi‑
tor), imatinib (Bcr‑Abl, cKIT, RET, NGF‑R, PDGFRα/β, 
ABL1, M‑CSFR). mTOR plays a role in the control of 
numerous basic biological functions such as proliferation 
and migration and acts as a nutriment sensor. One of the best 
inhibitors used in clinic is rapamycin (sirolimus) which can 
inhibit mTOR after its binding to FKBP12 and acts as an 
immunosuppressive agent. Bernstein‑Molho et al. analysed 
the effect of mTOR inhibition by sirolimus combined with 
cyclophosphamide in a series of 49 recurrent unresectable 
chondrosarcomas [136]. The combination of both agents 
was well tolerated with no significant adverse effects and 
could have therapeutic benefit. Indeed, 10% of objective 
response and 60% of stabilisation of disease for at least 6 
months were observed. A phase II clinical trial is on‑going 
associating both agents in unresectable chondrosarcoma 
(NCT02821507, Table 3). Everolimus, targeting mTORC1 
(mTOR complex 1), appeared efficacious as single agent in a 
rat chondrosarcoma model [137] and a phase II clinical trial 
has been designed to evaluate its therapeutic efficacy in pri‑
mary or relapsed chondrosarcoma (NCT02008019, Table 3).
IDH‑1 or ‑2 are frequently mutated in malignant cartilagi‑
nous tumours and two phase I clinical trials are in progress 
with AG‑120, a mutant IDH‑1 inhibitor (NCT02073994) and 
AG‑221, a mutant IDH2 inhibitor (NCT02273739).
Chondrosarcoma development is associated with the infil‑
tration of immune cells [65]. In an in vivo rat chondrosar‑
coma model, Simard et al. demonstrated a positive impact 
on tumour growth after selective T cell depletion in contrast 
to the depletion of  CD163+ macrophages resulting in a slow‑
down of tumour development [65]. These results showed the 
clear implication of the immune system on the pathogenesis 
of chondrosarcoma and the clinical interest to assess new 
inhibitors of immune checkpoints. These observations were 
confirmed more recently by Kostine et al. who demonstrated 
that 41–52% of dedifferentiated chondrosarcomas displayed 
PD‑L1 positivity [138]. A phase II clinical trial is on‑going 
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and patients will be treated by intravenous pembrolizumab 
at 200 mg every 3 weeks (NCT02301039, Table 3).
Giant Cell Tumours of Bone: Benign Tumours 
with Malignant‑Like Properties
In the field of bone sarcoma, giant cell tumours (GCTs) have 
a special status. Indeed, GCTs are benign tumours with no 
nuclear cytologic aberration, intensively damaging the host 
bone and the cells can spread to the soft tissue in a similar 
manner to a malignant tumour [139–141]. Indeed, high‑
grade malignant neoplasm can be identified at the time of 
diagnosis or subsequent surgery (secondary malignancy in 
GCT) or radiotherapy. Giant cell tumours of bone are rare 
tumours with an incidence of around 1 new case per 100,000 
people per year and affect mainly young adults on the second 
and third decade. The ratio male/female of 1:2 is in favour 
of the female. The tumour tissue is characterised by three 
main cellular components: (i) giant multinucleated cells 
(osteoclast‑like cells), (ii) mononuclear macrophages and 
(iii) mononuclear stromal cells (Fig. 4). Stromal cells secrete 
numerous pro‑myeloid factors such as M‑CSF and pro‑
osteoclastic factors such as RANKL resulting in monocyte/
macrophage proliferation and osteoclastogenesis. Indeed, 
osteoclast precursors have monocytic/macrophagic origin 
and can proliferate, fuse and differentiate in the presence 
of M‑CSF and RANKL (Fig. 4). RANKL is mandatory for 
osteoclastogenesis. RANKL binds to three distinct recep‑
tors: (i) RANK: a transmembrane receptor expressed at the 
surface of osteoclasts and their precursors and is responsi‑
ble for osteoclast differentiation; (ii) OPG: a soluble decoy 
receptor blocking the binding of RANKL to RANK and 
therefore considered as an anti‑bone catabolic agent, (iii) 
LGR‑4 expressed at the cell membrane of osteoclasts and 
which negatively regulates osteoclast differentiation (Fig. 4) 
[142]. The origin of giant cell tumours of bone has been con‑
troversial for a long time. Nowadays, it is widely accepted 
that the stromal component is “the tumoural” element of the 
tissue and its dysregulation leads to the recruitment, pro‑
liferation and differentiation of macrophages. The clinical 
consequence is massive local bone destruction (Fig. 4). The 
current treatment is based on a resection surgery but unfor‑
tunately frequent recurrences associated with a high morbid‑
ity are observed. This is followed by a possible malignant 
transformation with a metastatic profile after up to 20 years.
Similar to other bone sarcomas, the local microenvi‑
ronment is crucial in the tumour development and the 
osteolytic process. In this context, anti‑bone resorption 
agents have been assessed in clinical trials with great suc‑
cess [143, 144]. A phase II clinical trial (NCT01564121) 
has assessed zoledronic acid in 24 patients [144]. The 
patients were treated with extensive intralesional curettage 
followed by five courses of bisphosphonate. Unfortunately, 
even if short adjuvant treatments with zoledronic acid were 
associated with a low rate of recurrence, the study did not 
show any significant impact on local recurrence. Deno‑
sumab, a humanised blocking antibody against RANKL, is 
currently evaluated in a series of 586 patients in a phase II 
clinical trial (NCTNCT00680992) [102]. Denosumab was 
administered subcutaneously at a dose of 120 mg every 
4 weeks and a loading dose of 120 mg s.c. on study days 8 
and 15. The intermediate results showed the safety of the 
drug and first clinical benefit with at least 90% of tumour 
necrosis after denosumab administration (estimated com‑
pletion date: end 2017). Preoperative pretreatment is cur‑
rently in discussion to facilitate the surgical resection in 














Fig. 4  Giant cell tumours of bone: a benign entity with malignant 
features. Giant cell tumours of bone are composed of three main cell 
populations: stromal cells, macrophages and multinucleated oste‑
oclast‑like cells. These tumours are responsible for a marked local 
bone resorption leading to the formation of large osteolytic foci easily 
detectable by X‑ray radiography. RANKL/M‑CSF and/or RANKL/
IL‑34 released by stromal cell could induce the differentiation of 
macrophages considered as osteoclast precursors towards immature 
and mature osteoclasts resorbing bone. Soluble OPG and membrane 
LGR4 are two receptors that negatively control osteoclastogen‑
esis. OPG acts as a decoy receptor to RANK resulting in blocked 
RANKL–RANK interactions. LGR4 is expressed by osteoclasts and 
binds to RANKL leading to Gαq/GS3K‑β signalling and repression 
of the NFATc1 molecular pathway. IL-34 Interleukin‑34, LGR-4 
G‑protein‑coupled receptor 4, M-CSF Macrophage Colony‑Stimulat‑
ing Factor, OPG osteoprotegerin, RANKL Receptor of Nuclear factor 
kappaB Ligand
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Conclusion
Bone sarcomas are rare and heterogeneous diseases. Most 
bone sarcomas originate from MSCs and share a common 
feature with a marked implication of the local environment 
in their pathogenesis. This microenvironment appears as an 
impressive source of therapeutic targets and is leading to 
the design of numerous promising clinical trials. However, 
the tumour microenvironment of bone sarcomas is also very 
heterogeneous and includes numerous cell types, all of them 
composed by heterogeneous sub‑clones. A better characteri‑
sation is the key challenge for a better patient stratification 
and development of personalised medicine.
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